Project Grant R21AI183188
Award Date
9/26/24
Completion Date
8/31/26
Dollars Obligated
$248K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $755,225 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Loyola University of Chicago to develop a novel pan-coronavirus vaccine. The goal is to create a vaccine targeting conserved coronavirus antigens (S2, M, and N proteins) from both the Sarbecovirus and Merbecovirus lineages, in order to provide broad protection against future emerging pandemic coronaviruses. The project will...
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...
The University of California, Irvine (UCI) was awarded a $33,116,067 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to conduct basic and translational research to develop prototype vaccines against emerging viruses using two universal, programmable vaccine platforms: adjuvanted recombinant protein (ARP) and mRNA/lipid nanoparticle (LNP) vaccines. The research...
This federal Project Grant award, with ID R01AI190286, is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $899,935 award will support research at the Scripps Research Institute to identify novel B cell epitopes on the SARS-CoV-2 spike protein and other human coronaviruses. The goal is to uncover conserved and cryptic epitopes that can elicit broadly neutralizing antibodies, which could...
This $2,178,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a "tunable nanophage platform" for rapid vaccine design and screening against emerging infectious disease threats. The key objectives are to engineer "second generation" nanophage particles that can display the spike receptor binding domains of SARS-CoV-2 and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,516 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Kentucky Research Foundation. The grant supports research to understand the mechanism of SARS-CoV-2 viral entry by applying single-molecule approaches. The proposed work aims to measure the binding dynamics of the SARS-CoV-2 spike protein and ACE2 receptor, study the detachment kinetics and...
This $598,752 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify and design broadly acting antibodies targeting the S2 subunit of the SARS-CoV-2 spike protein. The research project will evaluate the functional properties of these S2-targeting antibodies using neutralization assays, in vitro Fc-effector function assays, and systems serology approaches. The goal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The funding will support research to assess the potential for "germline targeting" vaccine design to elicit broadly neutralizing antibodies (bNAbs) against the influenza virus neuraminidase (NA) protein. Key activities include evaluating recently discovered NA bNAbs to identify...
The University of Washington received a $41,075,241 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award is for a project titled "Machine Learning-Enabled Design of Prototype Pathogen Vaccines and Antibodies" and will run from August 2024 to July 2027. The project aims to develop end-to-end strategies for pandemic preparedness vaccine development, focusing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $705,557.00 in funding to Emory University to investigate the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The research aims to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, as well as define the effector mechanisms...